Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06347796 · ClinicalTrials.gov registry record · NA

Chronic Subdural Hematoma Treatment With Embolization Versus Surgery Study

A NA study of Chronic Subdural Hematoma, sponsored by The University of Texas Medical Branch, Galveston.

Recruiting
Registry status
NA
Development phase
520
Enrollment target
20
Study locations

NCT06347796 is a NA study of Chronic Subdural Hematoma that is actively recruiting participants, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 520 participants, below the 1,312-participant average among 4 other Chronic Subdural Hematoma trials with a reported enrollment target (60% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06347796, a NA study of Chronic Subdural Hematoma, is actively recruiting participants, sponsored by The University of Texas Medical Branch, Galveston.

RECRUITING
Registry status
NA
Development phase
520 participants
Enrollment target
20
Study locations

Study Summary

The goal of this clinical trial is to test in moderately symptomatic chronic subdural hematoma (CSDH) patients if middle meningeal artery embolization (MMAE) can be used as an alternative to conventional open surgery. The main questions it aims to answer are: * Compared to open conventional surgery, does MMAE reduce the need for rescue surgery or deaths? * What is the safety of MMAE and conventional open surgery in these patients? Participants will be asked to: * Share their medical history and undergo physical examinations * Have blood drawn * Have CT scans of the head * Answer questionnaires * Undergo MMAE or conventional open surgery * Provide information about possible adverse events Researchers will compare participants in the MMAE group with those in the conventional open surgery group to see if there is a reduced need for rescue surgery or deaths and evaluate safety.

Conditions Studied

Interventions

  • PROCEDURE Conventional Surgery
  • DEVICE Middle Meningeal Artery Embolization (MMAE)

Study Locations (20)

New York

  • Ichan School of Medicine at Mount Sinai - New York
  • SUNY Upstate Medical University - Syracuse
  • Montefiore Medical Center - The Bronx
  • Westchester Medical Center - Valhalla

Florida

  • Baptist Medical Center Jacksonville - Jacksonville
  • University of Miami Miller School of Medicine - Miami
  • University of South Florida - Tampa

Massachusetts

  • Massachusetts General Hospital - Boston
  • Brigham and Women's Hospital - Boston
  • Beth Israel Deaconess Medical Center - Boston

New Jersey

  • Cooper University Hospital - Camden
  • JFK Neuroscience Institute, JFK University Medical Center - Edison
  • Rutgers, The State University of New Jersey - Newark

Missouri

  • University of Missouri Healthcare - Columbia
  • Washington University, St. Louis - St Louis

Arizona

  • Mayo Clinic Arizona - Phoenix

Georgia

  • Emory University - Atlanta

Kansas

  • University of Kansas Medical Center - Kansas City

Trial Details

FieldValue
Enrollment Target 520 participants
Start Date 2024-11-01
Est. Completion 2029-02
Phase NA

What the Registry Record Tells You About NCT06347796

The ClinicalTrials.gov registry entry for NCT06347796 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 520 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,312-participant average among 4 other Chronic Subdural Hematoma trials with a reported enrollment target (60% lower). The listed sponsor is The University of Texas Medical Branch, Galveston, which has 203 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Subdural Hematoma appearing as the primary indexed condition, and to 2 interventions - of which Conventional Surgery is the first listed.

NCT06347796 reports 20 study locations spanning 10 distinct geographic areas - top geographies include New York, Florida, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06347796 about?

NCT06347796 is a clinical study titled "Chronic Subdural Hematoma Treatment With Embolization Versus Surgery Study". The goal of this clinical trial is to test in moderately symptomatic chronic subdural hematoma (CSDH) patients if middle meningeal artery embolization (MMAE) can be used as an alternative to conventional open surgery. The main questions it aims to answer are: * Compared to open conventional surgery...

What is the current status of trial NCT06347796?

This trial is currently recruiting. It is a NA study. The enrollment target is 520 participants. The study started on 2024-11-01. Estimated completion is 2029-02.

What conditions does trial NCT06347796 study?

This clinical trial studies the following conditions: Chronic Subdural Hematoma.

What interventions are being tested in trial NCT06347796?

The interventions under investigation include: Conventional Surgery (PROCEDURE), Middle Meningeal Artery Embolization (MMAE) (DEVICE).

Who is sponsoring clinical trial NCT06347796?

This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06347796 being conducted?

This trial has 20 study locations across Arizona, Florida, Georgia, Kansas, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Subdural Hematoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.